Top

World Journal of Urology

Published in:

17-07-2023 | Benign Prostatic Hypertrophy | Original Article

The nano-micellar curcumin improves International Prostate Symptoms Score (IPSS) in patients with benign prostatic hyperplasia: a randomized clinical trial

Authors: Ali Akbar Karami, Hoda Zameni, Mitra Salehi, Seyyed Mehdi Mirhashemi

Published in: World Journal of Urology | Issue 9/2023

Abstract

Purpose

Benign prostatic hyperplasia (BPH) is the main prevalent disorder in men over forty years, usually revealing itself with lower urinary tract symptoms. Despite the existence of different treatments, the incidence of BPH is increasing, so further studies for better management are a necessity. This research was designed to assay the effectiveness of nano-micellar curcumin on biomedical indicators of patients with BPH.

Methods

The present research was a double-blind, randomized, and placebo-controlled trial that enrolled fifty-two patients with BPH between June 2021 and December 2021. Participants were randomized to receive 160 mg/d nano-micellar curcumin (n = 26) or placebo (n = 26) as soft gel during 3 months. Primary end point was changes in International Prostate Symptoms Score (IPSS). Data gathering was occurred using a standard inquiry form and measuring other biomedical parameters based on routine laboratory techniques. To compare the distribution of demographics and covariates, independent t-test and Chi-square were used.

Results

Nano-micellar curcumin had significant effect on IPSS (p value: 0.010), low effect on high-sensitive C-reactive protein (hs-CRP) (p value: 0.032), and low to intermediate effect on malondialdehyde (MDA) (p value: 0.014) level as secondary end points after the intervention. The effect of nano-micellar curcumin on other parameters was negligible.

Conclusion

Overall, this trial indicated 3-month intake of nano-micellar curcumin had considerable effects on IPSS as the most common clinical symptom and also two biomedical parameters including serum hs-CRP and MDA.

Trial registration

http://www.irct.ir: IRCT20170430033730N3.

AbdelRazek M, Abolyosr A, Mhammed O, Fathi A, Talaat M, Hassan A (2022) Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World J Urol 40:2063–2013. https://doi.org/10.1007/s00345-022-04071-7CrossRefPubMedPubMedCentral

Guo Z, He J, Huang L, Wang Z, Hu P, Wang S et al (2022) Prevalence and risk factors of incidental prostate cancer in certain surgeries for benign prostatic hyperplasia: a systematic review and meta-analysis. Int Braz J Urol 48:915–944. https://doi.org/10.1590/S1677-5538.IBJU.2021.0653CrossRefPubMedPubMedCentral

Rastrelli G, Cipriani S, Lotti F, Cellai I, Comeglio P, Filippi S et al (2022) Testosterone does not affect lower urinary tract symptoms while improving markers of prostatitis in men with benign prostatic hyperplasia: a randomized clinical trial. J Endocrinol Invest 45:1413–1438. https://doi.org/10.1007/s40618-022-01776-9CrossRefPubMedPubMedCentral

Plochocki A, King B (2022) Medical treatment of benign prostatic hyperplasia. Urol Clin North Am 49:231–239. https://doi.org/10.1016/j.ucl.2021.12.003CrossRefPubMed

Elterman D, Gao B, Lu S, Bhojani N, Zorn KC, Chughtai B (2022) New technologies for treatment of benign prostatic hyperplasia. Urol clin North Am 49:11–22. https://doi.org/10.1016/j.ucl.2021.07.007CrossRefPubMed

Romero Pérez P (2022) Post-finasteride syndrome. Literature review. Arch Esp Urol 75:382–481. https://doi.org/10.56434/j.arch.esp.urol.20227505.56CrossRefPubMed

Liu Y, Wang Z, Gan Y, Chen X, Zhang B, Chen Z et al (2021) Curcumin attenuates prostatic hyperplasia caused by inflammation via up-regulation of bone morphogenetic protein and activin membrane-bound inhibitor. Pharm Biol 59:1026–1061. https://doi.org/10.1080/13880209.2021.1953539CrossRefPubMed

Bagherniya M, Askari G, Alikiaii B, Abbasi S, Soleimani D, Sathyapalan T et al (2021) Curcumin for the treatment of prostate diseases: a systematic review of controlled clinical trials. Adv Exp Med Biol 1291:345–407. https://doi.org/10.1007/978-3-030-56153-6_20CrossRefPubMed

Ledda A, Belcaro G, Dugall M, Luzzi R, Scoccianti M, Togni S et al (2012) Meriva®, a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: a pilot, product evaluation registry study. Panminerva med 54:17–22PubMed

10.

Ide H, Lu Y, Noguchi T, Muto S, Okada H, Kawato S et al (2018) Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer. Cancer scie 109:1230–1238. https://doi.org/10.1111/cas.13517CrossRef

11.

AUA Practice Guidelines Committee (2003) AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 170:530–577CrossRef

12.

Calogero AE, Burgio G, Condorelli RA, Cannarella R, La Vignera S (2019) Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male 22(1):12–9. https://doi.org/10.1080/13685538.2018.1434772CrossRefPubMed

13.

Ma CH, Lin WL, Lui SL, Cai XY, Wong VT, Ziea E et al (2013) Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia systematic review of randomized controlled trials. Asian J Androl 15:471–553. https://doi.org/10.1038/aja.2012.173CrossRefPubMedPubMedCentral

14.

Javadi H, Yaghoobzadeh H, Esfahani Z, Reza Memarzadeh M, Mehdi Mirhashemi S (2019) Effects of olive leaf extract on metabolic response, liver and kidney functions and inflammatory biomarkers in hypertensive patients. Pak J Biol Sci 22:342–350. https://doi.org/10.3923/pjbs.2019.342.348CrossRefPubMed

15.

Miller LE, Te AE, Bhattacharyya SK, Lilienfeld S, Dornbier RA, McVary KT (2020) A novel metric for treatment durability in clinical trials of minimally invasive treatments for benign prostatic hyperplasia. Expert Rev Med Devices 17:365–374. https://doi.org/10.1080/17434440.2020.1742699CrossRefPubMed

16.

Akbar Karami A, Sheikhsoleimani M, Reza Memarzadeh M, Haddadi E, Bakhshpour M, Mohammadi N et al (2020) Urtica dioica root extract on clinical and biochemical parameters in patients with benign prostatic hyperplasia, randomized controlled trial. Pak J Biol Sci 23:1338–1382. https://doi.org/10.3923/pjbs.2020.1338.1344CrossRefPubMed

17.

Zerafatjou N, Amirzargar M, Biglarkhani M, Shobeirian F, Zoghi G (2021) Pumpkin seed oil (Cucurbita pepo) versus tamsulosin for benign prostatic hyperplasia symptom relief: a single-blind randomized clinical trial. BMC Urol 21:147–155. https://doi.org/10.1186/s12894-021-00910-8CrossRefPubMedPubMedCentral

18.

Sun F, Sun X, Shi Q, Zhai Y (2018) Transurethral procedures in the treatment of benign prostatic hyperplasia: A systematic review and meta-analysis of effectiveness and complications. Medicine 97:13360–13373. https://doi.org/10.1097/MD.0000000000013360CrossRef

19.

Kaya E, Ozgok Y, Zor M, Eken A, Bedir S, Erdem O et al (2017) Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: a prospective controlled study. Adv Clin Exp Med 26:1095–1104. https://doi.org/10.17219/acem/66837CrossRefPubMed

20.

Kim SK, Seok H, Park HJ, Jeon HS, Kang SW, Lee BC et al (2015) Inhibitory effect of curcumin on testosterone induced benign prostatic hyperplasia rat model. BMC Complemen Alter Med 15:380–387. https://doi.org/10.1186/s12906-015-0825-yCrossRef

21.

De Velasco MA, Lu Y, Kura Y, China T, Inoue Y, Nakayama A et al (2020) Chemopreventive effects of nanoparticle curcumin in a mouse model of Pten-deficient prostate cancer. Hum Cell 33:730–736. https://doi.org/10.1007/s13577-020-00337-7CrossRefPubMed

22.

Hodaei H, Adibian M, Nikpayam O, Hedayati M, Sohrab G (2019) The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial. Diabetol Metab Syndr 11:41–48. https://doi.org/10.1186/s13098-019-0437-7CrossRefPubMedPubMedCentral

23.

Cosentino V, Militello A, Lauria G (2018) Short-term effects of a dietary supplement on lower urinary tract symptoms. J Biol Regul Homeost Agents 32:1557–1620PubMed

24.

Crocerossa F, Bagalá L, Sicoli F et al (2023) Clinical effects of oral supplementation of gamma-ciclodextrin curcumin complex in male patients with moderate-to-severe BPH-related lower urinary tract symptoms. Res Square. 2:1–12. https://doi.org/10.21203/rs.3.rs-2572035/v1CrossRef

25.

Milanese G, Agostini E, De Angelis MV, Pretore E, Galosi AB et al (2023) Efficacy of 1-year cavacurmin® therapy in reducing prostate growth in men suffering from lower urinary tract symptoms. J Clin Med 12(4):1689–1697. https://doi.org/10.3390/jcm12041689CrossRefPubMedPubMedCentral

Title: The nano-micellar curcumin improves International Prostate Symptoms Score (IPSS) in patients with benign prostatic hyperplasia: a randomized clinical trial
Authors: Ali Akbar Karami
Hoda Zameni
Mitra Salehi
Seyyed Mehdi Mirhashemi
Publication date: 17-07-2023
Publisher: Springer Berlin Heidelberg
Keywords: Benign Prostatic Hypertrophy
Benign Prostatic Hypertrophy
Published in: World Journal of Urology / Issue 9/2023
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-023-04512-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The nano-micellar curcumin improves International Prostate Symptoms Score (IPSS) in patients with benign prostatic hyperplasia: a randomized clinical trial

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 9/2023

Retroperitoneal lymph node dissection for testicular cancer is a demanding procedure: detailed real-life data of complications and additional surgical procedures in 295 cases

The Mayo adhesive probability score predicts postoperative fever and intraoperative hemorrhage in mini-percutaneous nephrolithotomy

Racial disparities in new-onset diabetes mellitus in prostate cancer patients on androgen deprivation therapy: a retrospective analysis of TriNetX data

Post-chemotherapy robot-assisted retroperitoneal lymph node dissection for metastatic germ cell tumors: safety and perioperative outcomes

Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study

Clinical and time-related predictors of sepsis in patients with obstructive uropathy due to ureteral stones in the emergency setting